OneSource records Rs. 4,282 million revenue in Q4 FY26
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
Global specialty pipeline accelerates growth
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Healthcare leaders, policymakers, hospitals, and patient advocates discuss AI-driven healthcare, digital transformation, quality of life in cancer care
India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
Subscribe To Our Newsletter & Stay Updated